IMDYLLTRA® ▼(tarlatamab)
PATIENT ALERT CARD

TO BE COMPLETED BY THE PRESCRIBING DOCTOR

THIS PATIENT HAS RECEIVED IMDYLLTRA®

Patient name / phone number

Date and time of first IMDYLLTRA® infusion

Prescribing doctor name / phone number

Name of hospital / centre / institution

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to the Malta Medicine Authority, Sir Temi Zammit Buildings, Malta Life Science Park, San Gwann SGN 300 Malta of at http:/www.medicines authority.gov.mt/adrportal. Adverse reactions should also be reported to Cherubino Ltd on 21343270 or pharmacovigilance@cherubino.com.mt

[This Patient Card fulfills the conditions of the marketing authorization and has been approved by the competent authority.]

MMA approved 04 August 2026 Version 1

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

- This patient is being treated with IMDYLLTRA®, which is a bispecific T-cell engager (BiTE®) molecule.
- IMDYLLTRA® is used for the treatment of adult patients with small cell lung cancer (SCLC).
- IMDYLLTRA® may cause side effects which may be severe and life-threatening such as Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS).

The patient card can be downloaded from the Malta Medicines Authority's website following this link: https://medicinesauthority.gov.mt/rmm.

If this patient is experiencing any of the symptoms on this card, please contact the prescribing doctor immediately for further information.

IMPORTANT INFORMATION FOR PATIENTS/CAREGIVERS

IMDYLLTRA® can cause serious and/or life-threatening side effects, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS).

Call your prescribing doctor or seek emergency medical attention RIGHT AWAY if you experience ANY of these symptoms.

- Fever (38.0ºC or higher)
- Hypotension (low blood pressure)
- Trouble breathing
- Fast or irregular heartbeat
- Confusion, trouble speaking, memory or personality changes
- Dizziness or lightheadedness
- Severe headache
- Chills, shaking chills
- Severe nausea, vomiting, or diarrhea
- Seizure
- Loss of balance, weakness, numbness
- Extreme sleepiness or decreased consciousness

These are not all of the possible side effects of IMDYLLTRA®. Please refer to the Package Leaflet for a full list of possible side effects. You should always consult your prescribing doctor about taking other medications while taking IMDYLLTRA®.

IMPORTANT INFORMATION FOR PATIENTS/CAREGIVERS

You are required to stay within proximity of an appropriate healthcare setting such as the treatment hospital for 24 hours from the start of each IMDYLLTRA® infusion on Day 1 and Day 8, accompanied by a caregiver.

CONTACT your prescribing doctor if you experience any of the symptoms listed in this card.

SEEK emergency help if you cannot reach your prescribing doctor's office.

DO NOT drive or operate machinery if neurologic symptoms, such as dizziness, seizures and confusion occur until the symptoms resolve.